AZ-W-L-GORE-&-ASSOCIATES
W. L. Gore & Associates, Inc. (Gore) today announced receipt of CE Mark for the GORE® EXCLUDER® Conformable AAA Device, a product designed for the treatment of abdominal aortic aneurysms (AAA) in patients with challenging anatomies. This device is the latest addition in Gore’s growing portfolio of innovative solutions for the endovascular treatment of aortic disease. Leveraging Gore's AAA device experience which has benefited more than 250,000 patients worldwide*, this new device builds upon a history unmatched by currently available stent-grafts.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160602005312/en/
Gore’s innovative EVAR solution expands on the legacy of repositionability, durability, and patency established by the GORE® EXCLUDER® AAA Device. As well, it incorporates stent design elements similar to the Conformable GORE® TAG® Device to enable apposition in tortuous aortas. Approved for patients with either proximal aortic neck angles of up to 90 degrees or a minimum aortic neck length of 10 mm,** the new conformable AAA device allows for tailored treatment and crucial precision in more difficult anatomies.
“Before this approval, in order to qualify for EVAR, the patient had to fit a fairly narrow subset of anatomical criteria,” said Robert Rhee, MD, Chief of Vascular and Endovascular Surgery at Maimonides Medical Center in New York. “The GORE EXCLUDER Conformable AAA Endoprosthesis will expand the applicability of EVAR to patients traditionally considered to have anatomy too challenging for endovascular treatment.”
The device introduces Gore’s Active Control System. This technology allows physicians to angle the device to optimize conformability and maximize seal in the proximal aortic neck.
“With the GORE EXCLUDER Conformable Device, our EVAR solutions will offer the broadest treatment range of any supplier in the market,” said Ryan Takeuchi, Aortic Business Unit Leader at Gore. “The feedback received on this new product suggests a high level of interest from physicians seeking to treat challenging AAA anatomies. As we scale up operations to meet this demand, we look forward to bringing this valuable product to patients and physicians.”
The GORE EXCLUDER Conformable Device is part of the growing family of endovascular products that share a mission to effectively treat aortic disease, backed by Gore’s highly rated clinical support team and educational offerings. The comprehensive portfolio of products includes the first FDA approved off-the-shelf iliac branch device, the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE), indicated for the endovascular treatment of common iliac artery aneurysms or aortoiliac aneurysms. To round out the branched portfolio, studies are underway in the U.S. for the GORE® EXCLUDER® Thoracoabdominal Device and the GORE® TAG® Thoracic Branch Device.
* Based on the number of GORE® EXCLUDER® AAA Endoprosthesis
Trunk-Ipsilateral Legs distributed.
** For use in patients
with proximal aortic neck angles of up to 90 degrees with a minimum
aortic neck length of 15 mm, and in patients with proximal aortic neck
angles of up to 60 degrees with a minimum aortic neck length of 10 mm.
ABOUT W. L. GORE & ASSOCIATES
At Gore, we have provided creative therapeutic solutions to complex medical problems for 40 years. During that time, 40 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. Our extensive family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia and soft tissue reconstruction, staple line reinforcement materials, and sutures for use in vascular, cardiac, and general surgery. We are one of a select few companies to appear on all of the U.S. “100 Best Companies to Work For” lists since the rankings debuted in 1984.
Products listed may not be available in all markets. GORE®, EXCLUDER®, TAG®, and designs are trademarks of W. L. Gore & Associates.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160602005312/en/
Contact:
Chempetitive Group for W.L. Gore & Associates
Andrea Vuturo, +1
312-997-2436
GoreMedical@Chempetitive.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 14:00:00 CEST | Press release
Pivotal Study Advances to Establish Histotripsy as a Non-Thermal, Surgery-Free Alternative to Destroy and Liquefy Kidney Tumors HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison
Norwegian Tech Firm Builds Military Command Center in 24 Hours6.6.2025 13:45:00 CEST | Press release
Norwegian technology provider Cyviz has successfully developed a fully mobile and ballistic-proof command center - designed, configured, and made operational in just 24 hours. The solution was showcased during a military exercise led by the Dutch Ministry of Defence and has already sparked interest from NATO members and civil protection agencies across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606640770/en/ Cyviz demonstrates rapid deployment capability with a mobile, container-based control room for defense and crisis response Cyviz and its partners constructed the command room inside a 14-ton container designed for transport on standard military vehicles and resistant to machine gun fire. The unit was deployed at a military base in the Netherlands, where Cyviz was tasked with delivering a fully functional command-and-control environment, under strict time constraints and in a high-stakes simulation. "You do
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom